On March 23, 2022 Centenaire Biosciences reported the company had attracted a total of 20 billion won in Series A investment from SD Biosensor’s affiliates Bionote and SDB Investment on the 18th (Press release, Centenaire Biosciences, MAR 23, 2022, View Source [SID1234643838]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sanctnaire, which is developing an innovative antibody platform centered on the field of anti-cancer and immune disease treatment, has succeeded in attracting large-scale investment within 10 months of its establishment, and is developing, pipeline expansion, and additional platforms for clinical entry of its core pipeline ‘CTN001’. We plan to use the investment for technology development.

Centenaire, which has the goal of ‘development of innovative new drugs for the era of average lifespan of 100 years’ with the French word ‘Centenaire’ meaning 100 years as its motif, is based on its proprietary antibody platform technology to treat cancer, autoimmune diseases, and brain nerve diseases. We are building pipelines in various fields, including therapeutics.

Santnaire’s core pipeline, the next-generation HER2-targeting antibody ‘CTN001’, is indicated for HER2-low-expressing breast cancer, not HER2-positive breast cancer, which is targeted by existing HER2-targeting antibodies. HER2 low-expression breast cancer is a newly classified cancer type that accounts for more than 50% of all breast cancers, but has great market potential as there is no approved target treatment.

Yang Ki-hyuk, CEO of Sanctnaire, said, "With this Series A investment, we will begin full-scale development and expansion of the antibody pipeline using platform technology," and added, "We will develop safe and effective antibody drugs, starting with our flagship pipeline ‘CTN001’. "We will prove Nair’s differentiated value," he said.

He continued, "CTN001 showed strong efficacy in HER2-low-expressing carcinomas that do not respond to the HER2-targeting antibody Herceptin in preclinical trials," adding, "Antibody-drug complex (ADC) and T-cell engage, which have recently shown positive results and are expanding treatment options for cancer patients. "As there are limits to its use as a combination treatment for early-stage cancer due to safety issues, CTN001 will be an alternative to overcome this," he emphasized.

Meanwhile, Sanctnair is a new bio company established by researchers, including CEO Yang Ki-hyuk, who was a founding member of Medytox and oversaw R&D, to develop a next-generation antibody platform based on innovative antibody technology introduced from Medytox. Sanctnaire is discussing collaboration in various fields with BioNote, which participated in the Series A investment, along with cooperation with its affiliate Medytox, and is pursuing the establishment of a network with several domestic universities and research institutes to improve the efficiency of research and development.